12:56 PM
 | 
Oct 08, 2018
 |  BC Extra  |  Company News

FDA approves Leadiant therapy for ADA-SCID

Leadiant Biosciences Inc. said FDA approved Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency.

Approval of the pegylated recombinant adenosine deaminase enzyme replacement therapy is based on two Phase III trials in...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >